We welcome you to Acne Treatment Center
....more
Updates on Acne Vulgaris
Narrowband UV-B Phototherapy During Pregnancy and Folic Acid Depletion - Archives of Dermatology
Narrowband UV-B Phototherapy During Pregnancy and Folic Acid Depletion Archives of Dermatology We read with interest Zeichner's 1 case report of acne vulgaris during pregnancy treated successfully with narrowband UV-B (NB-UV-B) therapy. Generally, UV-B is considered a safe form of psoriasis therapy during pregnancy, and this may apply to acne ... |
Endpoints - Clinical Trials in Dermatology - Inflammatory Lesions Count is the ... - PR Newswire (press release)
Endpoints - Clinical Trials in Dermatology - Inflammatory Lesions Count is the ... PR Newswire (press release) This report details 'Endpoints- Clinical Trials in Dermatology', highlighting the five major dermatological disorders which are Alopecia, Acne Vulgaris, Herpes Zoster, Candidiasis and Atopic Dermatitis. The classification of the five major ... |
Research and Markets: Endpoints - Clinical Trials in Dermatology ... - Business Wire (press release)
Research and Markets: Endpoints - Clinical Trials in Dermatology ... Business Wire (press release) The report examines different aspects under clinical trial endpoints in dermatology such as analysis on major marketed drugs with an emphasis on safety and efficacy details, Phase II and Phase III clinical trial analysis for both completed and ongoing ... |
PhotoCure : announces completion of Visonac® study enrolment - 4-traders (press release)
PhotoCure : announces completion of Visonac® study enrolment 4-traders (press release) The Phase IIb trial is a randomized, double-blind, placebo controlled study in patients with moderate to severe acne vulgaris. It will measure safety and efficacy in patients aged 12 - 35 years, who will receive four treatments over a six week period. ... |
Xoma initiates Phase 2 trial of Gevokizumab drug - Pharmaceutical Business Review
Xoma initiates Phase 2 trial of Gevokizumab drug Pharmaceutical Business Review ... of novel antibody therapeutics, has commenced patient dosing in its Phase 2 proof-of-concept study to evaluate the efficacy and safety of Gevokizumab (XOMA 052), as a treatment for inflammatory lesions seen in moderate to severe acne vulgaris. ... XOMA Initiates Gevokizumab Phase 2 Study for Moderate to Severe Acne Vulgaris |
